$PLSE
Pulse Biosciences Inc

2019 Q2 Form 10-Q Financial Statement

#000162510119000019 Filed on May 03, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.150M $4.400M $5.380M
YoY Change -0.39% -18.22% 340.98%
% of Gross Profit
Research & Development $6.337M $5.842M $3.175M
YoY Change 60.03% 84.0% 83.84%
% of Gross Profit
Depreciation & Amortization $100.0K $162.0K $153.0K
YoY Change -50.0% 5.88% -19.47%
% of Gross Profit
Operating Expenses $11.65M $10.41M $8.724M
YoY Change 25.26% 19.33% 169.51%
Operating Profit -$11.36M -$10.08M -$8.668M
YoY Change 23.97% 16.27% 171.04%
Interest Expense $290.0K $330.0K $60.00K
YoY Change 107.14% 450.0% 50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$11.36M -$10.08M -$8.670M
YoY Change 24.02% 16.26% 170.94%
Income Tax
% Of Pretax Income
Net Earnings -$11.36M -$10.08M -$8.668M
YoY Change 23.97% 16.27% 171.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$548.0K -$487.4K -$514.8K
COMMON SHARES
Basic Shares Outstanding 20.71M 20.69M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.64M $52.80M $33.38M
YoY Change 55.05% 58.18% 76.99%
Cash & Equivalents $10.78M $8.536M $10.67M
Short-Term Investments $31.86M $44.27M $22.71M
Other Short-Term Assets $1.910M $550.0K $370.0K
YoY Change 64.66% 48.65% 48.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.55M $53.35M $33.74M
YoY Change 55.44% 58.12% 76.56%
LONG-TERM ASSETS
Property, Plant & Equipment $1.985M $2.056M $2.450M
YoY Change -18.31% -16.08% 744.83%
Goodwill $2.791M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.645M $208.0K $100.0K
YoY Change 1545.0% 108.0%
Total Long-Term Assets $12.48M $10.10M $11.06M
YoY Change 14.84% -8.68% 16.91%
TOTAL ASSETS
Total Short-Term Assets $44.55M $53.35M $33.74M
Total Long-Term Assets $12.48M $10.10M $11.06M
Total Assets $57.03M $63.45M $44.80M
YoY Change 44.28% 41.63% 56.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.577M $1.200M $940.0K
YoY Change 5.13% 27.66% 20.51%
Accrued Expenses $1.703M $1.920M $850.0K
YoY Change 46.81% 125.88% 84.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.448M $3.115M $2.190M
YoY Change 12.31% 42.24% 76.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.720M $1.220M $1.510M
YoY Change 163.83% -19.21%
Total Long-Term Liabilities $3.720M $1.220M $1.510M
YoY Change 163.83% -19.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.448M $3.115M $2.190M
Total Long-Term Liabilities $3.720M $1.220M $1.510M
Total Liabilities $7.172M $4.338M $3.700M
YoY Change 60.09% 17.24% 198.39%
SHAREHOLDERS EQUITY
Retained Earnings -$97.16M -$85.80M
YoY Change
Common Stock $147.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.86M $59.11M $41.10M
YoY Change
Total Liabilities & Shareholders Equity $57.03M $63.45M $44.80M
YoY Change 44.28% 41.63% 56.81%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$11.36M -$10.08M -$8.668M
YoY Change 23.97% 16.27% 171.04%
Depreciation, Depletion And Amortization $100.0K $162.0K $153.0K
YoY Change -50.0% 5.88% -19.47%
Cash From Operating Activities -$9.690M -$7.330M -$5.018M
YoY Change 69.41% 46.07% 100.72%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K $45.00K $34.00K
YoY Change -57.14% 32.35%
Acquisitions
YoY Change
Other Investing Activities $12.62M -$35.69M $12.03M
YoY Change 515.61% -396.67% -764.64%
Cash From Investing Activities $12.55M -$35.73M $12.00M
YoY Change 557.07% -397.78% -762.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $272.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -610.0K 494.0K 300.0K
YoY Change 916.67% 64.67% -93.96%
NET CHANGE
Cash From Operating Activities -9.690M -7.330M -5.018M
Cash From Investing Activities 12.55M -35.73M 12.00M
Cash From Financing Activities -610.0K 494.0K 300.0K
Net Change In Cash 2.250M -42.57M 7.281M
YoY Change -158.14% -684.63% 1003.18%
FREE CASH FLOW
Cash From Operating Activities -$9.690M -$7.330M -$5.018M
Capital Expenditures -$60.00K $45.00K $34.00K
Free Cash Flow -$9.630M -$7.375M -$5.052M
YoY Change 72.58% 45.98% 102.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001625101
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20710406
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Pulse Biosciences, Inc.
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dei Trading Symbol
TradingSymbol
plse
CY2018Q4 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
156000
CY2017Q1 plse Area Of Lease
AreaOfLease
15700
CY2019Q1 plse Fair Value Equity Level12 And3 Transfers Amount
FairValueEquityLevel12And3TransfersAmount
0
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
274000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1421000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1272000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
992000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1154000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
142032000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3420000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2361000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3420000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2361000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3078237
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3307861
CY2018Q4 us-gaap Assets
Assets
70640000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
60362000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
59183000
CY2019Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52038000
CY2018Q1 us-gaap Available For Sale Securities Transfers To Trading Gains Losses Net
AvailableForSaleSecuritiesTransfersToTradingGainsLossesNet
48000
CY2019Q1 us-gaap Available For Sale Securities Transfers To Trading Gains Losses Net
AvailableForSaleSecuritiesTransfersToTradingGainsLossesNet
3000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3386000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10667000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51103000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8536000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7281000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-42567000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20593000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20710000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20593000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20710000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8620000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10075000
CY2018Q1 us-gaap Depreciation
Depreciation
153000
CY2019Q1 us-gaap Depreciation
Depreciation
162000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
938000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2772000
CY2019Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2939000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1222000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
665000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
499000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
665000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
665000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
665000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
665000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5213000
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5046000
CY2019Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5383000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4401000
CY2014Q4 us-gaap Goodwill
Goodwill
2800000
CY2018Q4 us-gaap Goodwill
Goodwill
2791000
CY2019Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
162000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-72000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-188000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
98000
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
107000
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-97000
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
6000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-44000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-229000
CY2018Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
56000
CY2019Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
332000
CY2018Q1 us-gaap Interest Income Operating
InterestIncomeOperating
56000
CY2019Q1 us-gaap Interest Income Operating
InterestIncomeOperating
332000
CY2018Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
10000
CY2019Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
96000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1924000
CY2018Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2019Q1 us-gaap Liabilities
Liabilities
4338000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63452000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3115000
CY2019Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
44265000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
8724000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
10410000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
392000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
574000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
554000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
404000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
305000
CY2018Q4 us-gaap Liabilities
Liabilities
4306000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70640000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3108000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
8480000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
494000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11999000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35731000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5018000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7330000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8668000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-10078000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1619000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
396000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1223000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
132000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
57000
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
59000
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y5M1D
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
101000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
19157000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
44186000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
550000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
208000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
779000
CY2019Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Reclassification</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassifications did not impact the Company's previously reported net loss or financial position.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
188000
CY2019Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
272000
CY2018Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
6315000
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8500000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24875000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
112000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
222000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3165000
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3210000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2173000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2056000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3175000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5842000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75718000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85796000
CY2018Q1 us-gaap Revenues
Revenues
CY2019Q1 us-gaap Revenues
Revenues
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
107000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3420000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2361000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
45995000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
41095000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
66334000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
59114000
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
188000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
222000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
112000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
272000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:10pt 0pt 0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the Financial Statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16842000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20679000

Files In Submission

Name View Source Status
0001625101-19-000019-index-headers.html Edgar Link pending
0001625101-19-000019-index.html Edgar Link pending
0001625101-19-000019.txt Edgar Link pending
0001625101-19-000019-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
plse-20190331.xml Edgar Link completed
plse-20190331.xsd Edgar Link pending
plse-20190331x10q.htm Edgar Link pending
plse-20190331xex31_1.htm Edgar Link pending
plse-20190331xex31_2.htm Edgar Link pending
plse-20190331xex32_1.htm Edgar Link pending
plse-20190331_cal.xml Edgar Link unprocessable
plse-20190331_def.xml Edgar Link unprocessable
plse-20190331_lab.xml Edgar Link unprocessable
plse-20190331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending